Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin

Polyphor receives award of up to USD 3.3 million from Cystic Fibrosis Foundation to support clinical development of inhaled murepavadin

Published

News published by Polyphor concerning the development of inhaled murepavadin, administered via an eFlow® Technology nebulizer.
 

Read the press release

Back to overview